Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PNMT | P11086 | 9/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8008337 | 0.82 | CA1 (0.59) | PNMTADRA2AADRA2BADRA2CCA12 | |
| SCHEMBL3803914 | 0.82 | CA1 (0.59) | PNMTADRA2AADRA2BADRA2CCA12 | |
| SCHEMBL8370641 | 0.81 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL20826329 | 0.80 | EPHX2 (0.51) | DRD2EPHX2CA12CA1CA2 | |
| SCHEMBL390212 | 0.80 | EPHX2 (0.51) | DRD2EPHX2CA12CA1CA2 | |
| SCHEMBL3441770 | 0.79 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL6558753 | 0.79 | CA12 (0.61) | PNMTADRA2AADRA2BADRA2CCA12 | |
| SCHEMBL5598167 | 0.79 | EPHX2 (0.50) | DRD2EPHX2CA12CA1CA2 | |
| SCHEMBL31324550 | 0.79 | EPHX2 (0.50) | EPHX2CA12CA1CA2CA7 | |
| SCHEMBL1545000 | 0.79 | EPHX2 (0.50) | DRD2EPHX2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014145512-A2 | POTENT SMALL MOLECULE INHIBITORS OF AUTOPHAGY, AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-1259484-B1 | CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION | NOVARTIS AG (CH) | 2005-05-18 | — | — | EP | disclosed |
| US-6878707-B2 | Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| US-20030109700-A1 | Carboxamides useful as inhinitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion | NOVARTIS AG (CH) | 2003-06-12 | — | — | US | disclosed |
| EP-1259484-A1 | CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION | Novartis AG (CH) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001053260-A1 | CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION | NOVARTIS AG (CH) | 2001-07-26 | — | — | WO | disclosed |
| EP-1097129-A1 | N-BENZOCYCLOALKYL-AMIDE DERIVATIVES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2001-05-09 | — | — | EP | disclosed |
| US-6197798-B1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN | NOVARTIS AG (CH) | 2001-03-06 | — | — | US | disclosed |
| WO-2001005767-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000005201-A1 | N-BENZOCYCLOALKYL-AMIDE DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109700-A1 | Carboxamides useful as inhinitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion | APOB, CETP, MTTP | DRD2 1004/4885EPHX2 1849/4885MAPT 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.